Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the National Institute for Health and Care Excellence on when it plans to conclude its appraisal of trastuzumab deruxtecan for treating HER2-low metastatic or unrespectable breast cancer after chemotherapy.

We have had no such discussions. The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on trastuzumab deruxtecan for HER2-low metastatic or unresectable breast cancer after chemotherapy, and recently consulted on draft guidance that does not recommend it as a clinically and cost-effective use of NHS resources. NICE will carefully consider comments received in response to the consultation in developing its final guidance, which is currently expected to be published in January 2024.